Review Article
Gingival Overgrowth: Drug-induced versus Hereditary and Idiopathic
Alyaa Ragaei1* and Rehab A Abdel Moneim21Department of Supplementary General Science, Future University, Cairo, Egypt
2Department of Oral Biology, Cairo University, Cairo, Egypt
- *Corresponding Author:
- Alyaa Ragaei
Department of Supplementary General Science
Future University, Cairo, Egypt
Tel: +201004684290
E-mail: alyaa_fue@yahoo.com
Received date: October 28, 2016; Accepted date: March 09, 2017; Published date: March 13, 2017
Citation: Ragaei A (2017) Gingival Overgrowth: Drug-induced versus Hereditary and Idiopathic. Cosmetol & Oro Facial Surg 3:113.
Copyright: © 2017 Ragaei, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Gingival overgrowth (GO) is the abnormal enlargement of maxillary and mandibular gingiva. It can be caused due to different etiological factors inherited (hereditary) gingival fibromatosis (HGF), accompanied with diseases characterizing syndrome; idiopathic gingival fibromatosis (IGF) or as a side effect of an adverse reaction (ADR) known as drug-induced gingival fibromatosis (DIGF). The hypertrophic gingiva is also accompanied with variable growth factors expression at cellular and levels. It is well observed in fibroblasts activity and production of collagenous fibers in connective tissues as well as their degradation. Thus, it would be useful to identify and explore different factors related to gingival growth changes to help in treatment plans. This review article will throw the light on systemic, pathological, histological and immuniohistochemical aspects associated with both HGF and DIGF.
